- Home
- NCNA vs ADXN Comparison
NCNA vs ADXN Comparison
Compare NCNA & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCNA | ADXN |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | United Kingdom | Switzerland |
| Employees | N/A | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 8.6M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NCNA | ADXN |
|---|---|---|
| Price | $2.09 | $7.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 33.9K | 4.4K |
| Earning Date | 06-01-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $5.41 |
| 52 Week High | $10.00 | $12.05 |
Technical Indicators
Market Signals| Indicator | NCNA | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 53.72 | 53.47 |
| Support Level | $2.07 | $5.49 |
| Resistance Level | $2.27 | $7.59 |
| Average True Range (ATR) | 0.17 | 0.59 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 64.18 | 72.60 |
Price Performance
Historical ComparisonAbout NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.